These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37611316)

  • 21. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
    Chen B; Hu N
    Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CB
    Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
    Elife; 2020 Nov; 9():. PubMed ID: 33210603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral CB1R as a modulator of metabolic inflammation.
    Han JH; Kim W
    FASEB J; 2021 Apr; 35(4):e21232. PubMed ID: 33715173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB
    Iyer MR; Cinar R; Katz A; Gao M; Erdelyi K; Jourdan T; Coffey NJ; Pacher P; Kunos G
    J Med Chem; 2017 Feb; 60(3):1126-1141. PubMed ID: 28085283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apparent CB
    Grim TW; Morales AJ; Thomas BF; Wiley JL; Endres GW; Negus SS; Lichtman AH
    J Pharmacol Exp Ther; 2017 Jul; 362(1):210-218. PubMed ID: 28442584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury.
    Kim SH; Won SJ; Mao XO; Jin K; Greenberg DA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):88-94. PubMed ID: 15626718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.
    Wu YK; Yeh CF; Ly TW; Hung MS
    Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.
    Hjorth S; Karlsson C; Jucaite A; Varnäs K; Wählby Hamrén U; Johnström P; Gulyás B; Donohue SR; Pike VW; Halldin C; Farde L
    Neuropharmacology; 2016 Feb; 101():519-30. PubMed ID: 25791528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
    Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
    Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
    Simon V; Cota D
    Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model.
    Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27928909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication.
    Sun LJ; Yu JW; Wan L; Zhang XY; Shi YG; Chen MY
    Int J Infect Dis; 2014 Jun; 23():75-81. PubMed ID: 24704332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Loss of Ghrelin Receptor and Cannabinoid CB1 Receptor in Mice Decreases Survival but does not Additively Reduce Body Weight or Eating.
    Mani BK; Castorena CM; Vianna CR; Lee CE; Metzger NP; Vijayaraghavan P; Osborne-Lawrence S; Elmquist JK; Zigman JM
    Neuroscience; 2020 Nov; 447():53-62. PubMed ID: 31520709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.
    Morgan DJ; Davis BJ; Kearn CS; Marcus D; Cook AJ; Wager-Miller J; Straiker A; Myoga MH; Karduck J; Leishman E; Sim-Selley LJ; Czyzyk TA; Bradshaw HB; Selley DE; Mackie K
    J Neurosci; 2014 Apr; 34(15):5152-63. PubMed ID: 24719095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Profiling of CB1 Neutral Antagonists.
    Seltzman HH; Maitra R; Bortoff K; Henson J; Reggio PH; Wesley D; Tam J
    Methods Enzymol; 2017; 593():199-215. PubMed ID: 28750803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.